Cerebello-spinal tDCS Reduced Symptoms of Neurodegenerative Ataxia
tDCS has been shown to be easily applicable, without significant adverse effects and relatively low-cost compared other pharmacologic treatments.
Bruce Trapp on Identifying Myelocortical Multiple Sclerosis
The Department Chair of Neurosciences at Cleveland Clinic was a leading part of the group of researchers that recently identified the new subtype of multiple sclerosis.
Lutz Frolich, MD, PhD: Learning from Negative Trials
Lutz Frölich, MD, PhD, spoke about the importance of continuing with research in light of negative trials in Alzheimer disease.
New Paths and Expansions in Multiple Sclerosis Treatments
Darin Okuda, MD, spoke about the new investigative therapies for MS, as well as the expanding role of disease-modifying therapies.
Treatment Options for CIDP
What is known about chronic inflammatory demyelinating polyradiculoneuropathy, a neurological disorder marked by by progressive weakness and impaired sensory function in the extremeties?
Myelocortical Multiple Sclerosis Identified as New Subtype
Investigators have identified a new subtype of MS in postmortem tissue, characterized by a lack of cerebral white matter demyelination.
AT132 Granted RMAT Designation for X-Linked Myotubular Myopathy
The designation is backed by positive interim data from ASPIRO, which has demonstrated significant improvements in neuromuscular and respiratory function at week 24.
Stiripentol Approved by FDA for Seizures Associated With Dravet Syndrome
The approval is backed by the effectiveness established in 2, 12-week studies in patients with Dravet syndrome, and open-label long-term studies.
Fludrocortisone for Cerebral Salt Wasting in Tuberculosis Meningitis Results in Earlier Serum Sodium Normalization
Patients treated with fludrocortisone normalized their serum sodium levels in only 4 days—significantly quicker than saline alone, which took 15 days.
Transcranial Direct Stimulation Shows Improvement in Patients With Post-Stroke Aphasia
Patients administered A-tDCS during outpatient speech therapy were shown to have a relative increase of 70% in correct-naming for A-tDCS compared to sham.
Excitement Building for New Agents in ALS
Several clinical trials are examining the role of stem cells, inflammation, and other pathways in ALS.
James Hendrix, PhD: Progress and Challenges in the Alzheimer Space
Hendrix spoke to the challenges he and colleagues come across, as well as his hope for the promising future.
Benzos, Related Z-drugs Associated With Increased Risk of Alzheimer Disease
A nationwide, case-controlled study found the use of benzodiazepines and related z-drugs increased the risk of patients developing Alzheimer disease.
Recent Multiple Sclerosis Developments With Tanuja Chitnis
The director of the Partners Pediatric Multiple Sclerosis Center at Massachusetts General Hospital spoke about the current landscape of MS treatment.
Matthew Robbins on the Current Therapeutic Landscape of Migraine Treatment
Robbins discusses the exciting future of true designer drugs in the works for migraine prevention as well as the challenges that remain in the space.
Predisposition to Seasickness: Who Is at Risk?
Seasickness can be difficult to manage once symptoms begin. However, there are some physiological characteristics to help patients manage symptoms.
Dennis Selkoe, MD: Current Challenges in Alzheimer Disease and Hope for the Future
Selkoe spoke to a number of topics in the Alzheimer space, including the challenges in the field and his excitement for the future.
Anti-TNF Therapy Reduces Parkinson Incidence in Patients with IBD
For those at-risk for Parkinson disease, reducing systemic inflammation could decrease the incidence of the movement disorder.
Lutz Frolich, MD, PhD: Collaboration Between Clinicians and Industry
Lutz Frölich, MD, PhD, discussed the imperativeness of collaboration between stakeholders—clinicians, pharmaceutical companies, researchers—in developing therapies for Alzheimer disease.
Brainsway Deep Transcranial Magnetic Stimulation System for OCD Approved by FDA
The results indicated that 38% of patients responded to the device whereas 11% of patients responded when using the sham device.
Nir Lipsman, MD, PhD: Innovations in Alzheimer Disease
The neurosurgeon from Sunnybrook Health Sciences Centre spoke about his excitement about where the medical community is at, at this point, in the understanding of Alzheimer disease.
Broad Range of Acute Neurological Illnesses Identified by AI Platform
This is the first study to utilize artificial intelligence for detecting a wide range of acute neurologic events, demonstrating a direct clinical application.
Timolol for Migraine Shows Efficacy as Abortive Therapy
The nonselective ß-blocker proved efficacious in comparison with placebo in a pilot trial.
WVE-210201 for Duchenne Muscular Dystrophy Receives Orphan Drug, Rare Pediatric Disease Designation by FDA
The investigational drug is in development for treatment of Duchenne muscular dystrophy patients amenable to exon 51 skipping.
Gill Livingston, MBChB, MD: Challenges of Sleep Difficulties in People Living with Dementia
Livingston spoke to a number of topics in the dementia space, including the challenges clinicians face and her hope for the future.
Treating Multiple Sclerosis with Disease-Modifying Therapies
Darin Okuda, MD, provides insight into the nuances that come with the treatment of MS with disease-modifying therapies.
Lutz Frolich, MD, PhD: Tempering Expectations for Alzheimer Disease Advancements
The head of the Department for Geriatric Psychiatry, Central Institute of Mental Health talked about the biggest challenges facing medicine in treating and understanding Alzheimer disease.
GSK, 23andMe Partnership Offers Opportunity for Development of Alzheimer, Parkinson Treatments
Could GlaxoSmithKline and 23andMe use genetic data to create landscape-altering therapies for hard-to-treat conditions?
Gill Livingston, MBChB, MD: Manual Based Intervention for Sleep Difficulties in Dementia
DREAMS-START demonstrates that a manual-based psychological treatment for sleep disorders in dementia is feasible and acceptable.
Lutz Frolich on Collaboration and Challenges in Alzheimer Research and Development
Can better collaboration between industry and clinicians solve the challenges that plague the Alzheimer community?
